HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy.

AbstractBACKGROUND:
Vasoreactivity testing is recommended in the management of pulmonary arterial hypertension (PAH), but its clinical relevance in congenital heart disease (CHD)-associated PAH has not been established.
OBJECTIVE:
To determine whether residual pulmonary vascular responsiveness to intravenous. epoprostenol is predictive of clinical outcome in patients with CHD-PAH and Eisenmenger syndrome.
METHODS AND RESULTS:
A diagnostic right heart catheterisation with reversibility testing using epoprostenol infusion was performed in 38 consecutive patients with CHD-PAH and Eisenmenger syndrome. Patients were treated with bosentan and were assessed every 3 months. Clinical worsening was defined as death from any cause, heart-lung or lung transplantation (or on the waiting list for this procedure), hospitalisation for PAH, or symptom exacerbation defined as a > or =20% decrease in the 6 min walking distance on two consecutive tests, an increase in WHO functional class, or worsening right heart failure. The mean follow-up was 33+/-17 months. Sixteen patients showed clinical worsening. Although they did not differ from the other patients in their baseline exercise capacity, haemodynamic characteristics and underlying CHD, pulmonary vascular resistance index (PVRi) was less reversible (DeltaPVRi 29+/-21 vs 52+/-14%, p=0.0003). At univariate analysis, systemic vascular resistance, PVRi and DeltaPVRi were significant predictors of clinical worsening. At multivariate Cox proportional hazards regression model, DeltaPVRi was found to be the only independent predictor of clinical worsening (HR=0.973, 95% CI 0.95 to 0.99; p=0.01). DeltaPVRi > or =25% had a positive and negative predictive value for clinical worsening of 100% and 75.9%, respectively.
CONCLUSION:
Pulmonary vasoreactivity is a significant predictor of clinical worsening in patients with CHD-PAH.
AuthorsMichele D'Alto, Emanuele Romeo, Paola Argiento, Giuseppe Santoro, Berardo Sarubbi, Giampiero Gaio, Christian Mélot, Maria Giovanna Russo, Robert Naeije, Raffaele Calabrò
JournalHeart (British Cardiac Society) (Heart) Vol. 96 Issue 18 Pg. 1475-9 (Sep 2010) ISSN: 1468-201X [Electronic] England
PMID20668108 (Publication Type: Journal Article)
Chemical References
  • Antihypertensive Agents
  • Sulfonamides
  • Epoprostenol
  • Bosentan
Topics
  • Adult
  • Antihypertensive Agents (therapeutic use)
  • Bosentan
  • Cardiac Catheterization (methods)
  • Eisenmenger Complex (drug therapy, physiopathology)
  • Epidemiologic Methods
  • Epoprostenol
  • Exercise Tolerance (physiology)
  • Female
  • Hemodynamics (physiology)
  • Humans
  • Hypertension, Pulmonary (drug therapy, physiopathology)
  • Male
  • Middle Aged
  • Prognosis
  • Pulmonary Artery (physiopathology)
  • Sulfonamides (therapeutic use)
  • Treatment Outcome
  • Vascular Resistance (drug effects)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: